Heart Failure Seminar: Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure - OnDemand-HF Seminar - : Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure (Handout)

HF Seminar - : Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure (Handout)

Pdf Summary

The HFSA Scientific Statement on Cardio-Oncology and Heart Failure underscores the interconnectedness of cancer and heart failure (HF) and the bidirectional risk these conditions pose to patients. The statement highlights several crucial areas where advancements and care improvements are needed:

1. <strong>Cardiac Surveillance and Monitoring</strong>: Although some cancer treatments like anthracyclines have established cardiac surveillance protocols, many therapies lack standardized guidelines, leading to inconsistent practices. This gap suggests the need for improved cardiac monitoring to mitigate risks.

2. <strong>Permissive Cardiotoxicity</strong>: A developing approach in cardio-oncology involves prioritizing cancer treatment efficacy even at the potential expense of cardiac health, with controlled cardiotoxicity managed through cardioprotective strategies.

3. <strong>Case-Based Discussions</strong>:
   - <strong>EGFR Inhibitors in Lung Cancer</strong>: EGFR-targeted therapies can induce cardiomyopathy, necessitating vigilance in cardiac assessments prior to and during treatment.
   - <strong>HER2 Breast Cancer Management</strong>: HER2-targeted therapies have been linked to heart failure, emphasizing the importance of integrating cardiovascular management with oncological care.
   - <strong>Immunotherapy-Induced Myocarditis</strong>: The use of immune checkpoint inhibitors can lead to severe and often life-threatening myocarditis, necessitating acute multidisciplinary intervention.

4. <strong>Advanced Therapies</strong>: For patients with chemotherapy-induced cardiomyopathy and advanced stage heart failure, options like LVADs offer viable survival rates. In cases complicated by cancer history, risk assessment is critical.

5. <strong>Future Directions and Recommendations</strong>: The document encourages comprehensive cardiac assessments for patients undergoing cancer therapy, emphasizing the importance of cardioprotective therapies like SGLT2 inhibitors and the role of immunomodulators in managing specific toxicities.

Collectively, these insights illustrate the need for dynamic and collaborative approaches in managing patients with concomitant cancer and heart failure, ensuring that life-saving therapies in one domain do not unduly compromise patient health in another.

Keywords

Cardio-Oncology

Heart Failure

Cardiac Surveillance

Cardiotoxicity

EGFR Inhibitors

HER2 Breast Cancer

Immunotherapy Myocarditis

Chemotherapy-Induced Cardiomyopathy

LVAD

Cardioprotective Therapies